ImpactLife Leukopak

Cell Starting Materials for Research Use Only and for Further Manufacturing

As a prominent national leader in blood and cell therapy collection with access to hundreds of thousands of donor registrants, ImpactLife offers premium leukopaks tailored for both research and cell starting materials for further manufacturing, streamlining your research and development processes.

These leukopaks support preclinical process development, clinical trials, and manufacturing, thus advancing basic research as well as the cell and gene therapy industry.

Additional Product Questions or Price Inquiries?

Why Choose ImpactLife Leukopak

the answer is within us

An ImpactLife leukopak is a collection of mononuclear cells derived through apheresis (MNC-A) and is used for research and further manufacturing rather than directly infused into a patient. We target a minimum of 9 billion mononuclear cells in each full leukopak.

Each leukopak is collected from donors who undergo infectious disease testing, meet standard donor eligibility criteria and who complete medical clearance from an apheresis center physician. This ensures that each donor’s safety is prioritized while committing to a safe collection process and product. Additional unique donor specifications can be requested for specialization in protocol needs. An IRB protocol including the donor consent will be performed to assure the right and welfare of the subjects.

Once collected, the product is tested within our laboratory facilities and shipped fresh, directly to your research facility for immediate use. We provide a certificate of analysis with each shipment that includes cell quantification.